Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer.

ABSTRACT: Cancer immunotherapy, including vaccination, is considered a major scientific and medical breakthrough. However, cancer immunotherapy does not result in durable objective responses against colorectal cancer (CRC). To improve the efficacy of immunotherapy, the present study investigated several biomarkers for selecting patients who were expected to respond well to immunotherapy. Firstly, a comprehensive proteomic analysis was performed using tumor tissue lysates from patients enrolled in a phase II study, in which five human leukocyte antigen (HLA)-A*24:02-restricted peptides were administered. Sialic acid-binding immunoglobulin type lectin (Siglec)-7 was identified as a potential predictive biomarker. Subsequently, this biomarker was validated using western blot analysis, and immunofluores

SUBMITTER: Yamada K 

PROVIDER: S-EPMC7681234 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature